M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works
in treating patients with stage II-III HER2 positive breast cancer. Immunotherapy with M7824
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread.